Ischemic Heart Disease (IHD), also known as coronary artery disease (CAD), remains a leading cause of morbidity and mortality worldwide. While revascularization strategies such as percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG) play an essential role, medical therapy remains the cornerstone of both symptom control and prognosis improvement. The primary goals of pharmacological treatment in IHD are:
- Relieve ischemic symptoms (anti-anginal therapy).
- Prevent myocardial infarction and death (secondary prevention).
- Reduce disease progression (lipid lowering and risk factor modification).
- Improve quality of life and exercise tolerance.
This article provides an in-depth exploration of the medical management of IHD, focusing on anti-anginal therapy, antiplatelet therapy, statins and lipid-lowering drugs, ACE inhibitors, and other adjunct therapies.
1. Anti-Anginal Therapy
Anti-anginal therapy is primarily aimed at restoring balance between myocardial oxygen supply and demand, thereby reducing ischemia and relieving angina symptoms.
1.1 Nitrates
Mechanism of Action:
- Nitrates (e.g., nitroglycerin, isosorbide mononitrate) release nitric oxide (NO), which activates guanylyl cyclase → ↑ cyclic GMP → smooth muscle relaxation.
- Main effect: Venodilation → reduced preload → decreased left ventricular wall stress → reduced oxygen demand.
- Also cause mild coronary vasodilation → ↑ myocardial oxygen supply.
Clinical Use:
- Sublingual nitroglycerin: rapid relief of acute angina (onset within 1–3 minutes).
- Long-acting nitrates (isosorbide mononitrate, nitroglycerin patches): prevention of angina episodes.
Limitations:
- Tolerance develops with continuous use → nitrate-free interval required (8–12 hours daily).
- Side effects: headache, flushing, hypotension, reflex tachycardia.
- Contraindicated with phosphodiesterase-5 inhibitors (sildenafil) → risk of severe hypotension.
1.2 Beta-Blockers
Mechanism of Action:
- Block β1-adrenergic receptors in the heart → ↓ heart rate, ↓ contractility, ↓ blood pressure.
- Result: Reduced myocardial oxygen demand.
- Increase diastolic filling time → improved coronary perfusion.
Clinical Benefits:
- First-line therapy for chronic stable angina and post-MI patients.
- Proven to reduce mortality and recurrent MI.
Examples:
- Cardioselective: Metoprolol, Bisoprolol, Atenolol.
- Non-selective: Propranolol.
- With α-blocking activity: Carvedilol, Labetalol.
Limitations:
- Side effects: bradycardia, fatigue, hypotension, bronchospasm (avoid in asthma).
- Contraindicated in severe bradycardia, AV block, acute decompensated heart failure.
1.3 Calcium Channel Blockers (CCBs)
Mechanism of Action:
- Inhibit L-type calcium channels in vascular smooth muscle and myocardium.
- Two subclasses:
- Dihydropyridines (DHPs): e.g., Amlodipine, Nifedipine → vasodilation, reduced afterload.
- Non-DHPs: Verapamil, Diltiazem → reduce heart rate and contractility.
Clinical Use:
- Alternative or adjunct to beta-blockers.
- Useful in patients with vasospastic (Prinzmetal) angina.
- Relieve angina by reducing afterload and improving coronary blood flow.
Limitations:
- Non-DHPs contraindicated with beta-blockers (risk of bradycardia, AV block).
- Side effects: hypotension, peripheral edema (DHPs), constipation (Verapamil).
1.4 Other Anti-Anginal Agents
- Ranolazine: Inhibits late sodium current → reduces myocardial wall tension and oxygen demand.
- Ivabradine: Selective sinus node inhibitor → slows heart rate without affecting contractility.
- Used in patients not tolerating standard therapy.
2. Antiplatelet Therapy
Platelet activation plays a critical role in atherothrombosis, the underlying mechanism of ACS. Antiplatelet therapy reduces risk of MI, stroke, and cardiovascular death.
2.1 Aspirin
Mechanism of Action:
- Irreversibly inhibits cyclooxygenase-1 (COX-1) → prevents thromboxane A2 formation → inhibits platelet aggregation.
Clinical Use:
- Lifelong low-dose aspirin (75–150 mg daily) recommended in all patients with IHD unless contraindicated.
Benefits:
- Reduces risk of recurrent MI and mortality.
Limitations:
- Risk of gastrointestinal bleeding and peptic ulceration.
- Contraindicated in aspirin allergy and active GI bleeding.
2.2 P2Y12 Inhibitors
Mechanism of Action:
- Block ADP-mediated platelet activation via P2Y12 receptor antagonism.
Examples:
- Clopidogrel (irreversible, prodrug).
- Prasugrel (irreversible, more potent, higher bleeding risk).
- Ticagrelor (reversible, rapid onset).
Clinical Use:
- In combination with aspirin as dual antiplatelet therapy (DAPT) for ACS or post-PCI with stent implantation.
- Monotherapy if aspirin contraindicated.
Benefits:
- Reduce stent thrombosis, recurrent MI, and mortality.
Limitations:
- Bleeding risk, drug interactions (clopidogrel with PPIs), variability in response (clopidogrel resistance).
2.3 Other Antiplatelet Agents
- Glycoprotein IIb/IIIa inhibitors (Abciximab, Eptifibatide, Tirofiban): potent IV agents used in high-risk ACS or PCI.
- Cangrelor: IV, reversible P2Y12 inhibitor, used during PCI when oral therapy is not feasible.
3. Statins and Lipid-Lowering Drugs
Dyslipidemia is a major risk factor for atherosclerosis. Lipid-lowering therapy not only reduces cholesterol but also stabilizes plaques, reducing ischemic events.
3.1 Statins (HMG-CoA Reductase Inhibitors)
Mechanism of Action:
- Inhibit hepatic HMG-CoA reductase → ↓ cholesterol synthesis → ↑ LDL receptor expression → ↓ LDL levels.
Clinical Benefits:
- First-line therapy for all patients with IHD, regardless of baseline cholesterol.
- Reduce cardiovascular morbidity and mortality.
- Stabilize atherosclerotic plaques by reducing lipid core.
Examples: Atorvastatin, Rosuvastatin, Simvastatin.
Limitations:
- Side effects: myopathy, rhabdomyolysis (rare), hepatotoxicity.
- Require monitoring of liver enzymes.
3.2 Ezetimibe
- Inhibits intestinal cholesterol absorption via NPC1L1 transporter.
- Used as add-on therapy to statins for further LDL reduction.
- Improves outcomes in high-risk IHD patients (e.g., IMPROVE-IT trial).
3.3 PCSK9 Inhibitors
- Monoclonal antibodies (Alirocumab, Evolocumab).
- Inhibit PCSK9 → ↑ LDL receptor recycling → dramatic LDL reduction.
- Used in high-risk patients with IHD and persistent hyperlipidemia despite statins.
3.4 Other Lipid-Modifying Drugs
- Fibrates (Gemfibrozil, Fenofibrate): Lower triglycerides, raise HDL. Limited use in IHD.
- Niacin: Raises HDL but limited by side effects (flushing, insulin resistance).
- Omega-3 fatty acids: May reduce triglycerides, but role in IHD prevention is limited.
4. ACE Inhibitors and Other Adjuncts
4.1 ACE Inhibitors (ACEIs)
Mechanism of Action:
- Inhibit conversion of angiotensin I to angiotensin II → vasodilation, ↓ afterload, ↓ preload.
- Reduce aldosterone secretion → ↓ sodium and water retention.
- Improve endothelial function and stabilize atherosclerotic plaques.
Clinical Use in IHD:
- Recommended for patients with IHD plus diabetes, hypertension, heart failure, or LV dysfunction.
- Reduce risk of MI, stroke, and cardiovascular death.
Examples: Ramipril, Perindopril, Lisinopril.
Limitations:
- Cough, hyperkalemia, renal dysfunction, angioedema.
- Contraindicated in bilateral renal artery stenosis and pregnancy.
4.2 Angiotensin Receptor Blockers (ARBs)
- Alternative to ACEIs in patients intolerant to cough.
- Examples: Losartan, Valsartan.
4.3 Aldosterone Antagonists
- Eplerenone, Spironolactone: reduce morbidity in post-MI patients with LV dysfunction and heart failure.
4.4 Other Adjunct Therapies
- Anticoagulants (Warfarin, DOACs): Used in IHD with atrial fibrillation or LV thrombus.
- SGLT2 inhibitors (Empagliflozin, Dapagliflozin): Emerging role in reducing cardiovascular mortality in diabetic IHD patients.
- Anti-inflammatory drugs: Colchicine being studied for reducing recurrent ischemic events.
5. Comprehensive Strategy for Medical Management
Management should be individualized based on patient risk profile, comorbidities, and tolerance.
5.1 Symptom Relief (Anti-anginal Therapy)
- First-line: Beta-blocker + nitrates as needed.
- Add-on: Calcium channel blocker or ranolazine.
5.2 Prognosis Improvement (Secondary Prevention)
- Aspirin + P2Y12 inhibitor (DAPT in ACS/PCI).
- Statin therapy (high-intensity).
- ACE inhibitor (especially in LV dysfunction, diabetes, hypertension).
- Lifestyle modifications: smoking cessation, diet, exercise, weight control.
5.3 Monitoring and Follow-Up
- Regular assessment of angina frequency and exercise tolerance.
- Monitor lipid profile, blood pressure, renal function, and HbA1c in diabetics.
- Adjust therapy based on side effects and clinical progression.
Leave a Reply